Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Mifoglame as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Clients benefit from reliable logistics and dedicated technical support throughout the supply chain.

Sitagliptin is used to manage hyperglycaemia in the type 2 diabetes mellitus therapeutic pathway.

Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. Metformin combination therapy: adds further HbA1c reduction in patients not achieving target with metformin alone. Insulin combination therapy: allows lower insulin doses by enhancing endogenous insulin secretion.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Upper respiratory tract infection: runny nose or sore throat. - Diarrhoea: loose stools, usually self‑limiting. - Nasopharyngitis: inflammation of the nasal passages. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angioedema, anaphylaxis, or skin rash. - Stevens‑Johnson syndrome: rare but life‑threatening skin eruption. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Renal impairment worsening: monitor kidney function closely.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events.

Renal function assessment: adjust dose in patients with reduced creatinine clearance. Hepatic impairment: use with caution in moderate to severe liver disease. Risk of hypoglycaemia: heightened when combined with insulin or sulfonylureas. Pancreatitis monitoring: discontinue if signs of pancreatic inflammation appear. Pregnancy and lactation: avoid unless benefits outweigh potential risks. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Sitagliptin may interact with several co‑administered medicines, requiring clinical vigilance.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas: additive hypoglycaemic effect. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma concentrations. - Diuretics: potential impact on glucose control. - ACE inhibitors: monitor renal function and electrolytes. - Digoxin: observe for any change in serum levels. - Warfarin: watch INR for possible variation.